RBMS3 and squamous cell lung carcinoma: From the clinical data, despite that down-regulated RBMS3 in lung squamous cell carcinoma (LSCC), nasopharyngeal carcinoma (NPC) and ESCC are found to strongly associate with unfavorable outcome [9, 10, 12], the expression and impacts of RBMS3 on GC progression is still unknown.